This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
acute respiratory | 524 |
respiratory syndrome | 480 |
severe acute | 405 |
respiratory tract | 342 |
novel coronavirus | 341 |
united states | 331 |
coronavirus disease | 330 |
public health | 304 |
viral load | 301 |
infectious diseases | 249 |
infect dis | 245 |
clin infect | 244 |
dis doi | 242 |
cord uid | 242 |
doc id | 242 |
acquired pneumonia | 220 |
syndrome coronavirus | 214 |
risk factors | 206 |
symptom onset | 192 |
health care | 185 |
respiratory viruses | 175 |
hospitalized patients | 162 |
ciaa sha | 158 |
cid ciaa | 158 |
respiratory syncytial | 155 |
syncytial virus | 151 |
lower respiratory | 147 |
nucleic acid | 143 |
upper respiratory | 136 |
respiratory symptoms | 134 |
hong kong | 132 |
clinical characteristics | 131 |
severe covid | 127 |
virus infection | 124 |
potential conflicts | 123 |
chain reaction | 123 |
influenza virus | 123 |
disease control | 122 |
clinical trials | 121 |
respiratory virus | 119 |
transplant recipients | 117 |
polymerase chain | 117 |
household contacts | 115 |
cohort study | 115 |
contact tracing | 110 |
middle east | 107 |
mechanical ventilation | 106 |
east respiratory | 104 |
world health | 103 |
systematic review | 102 |
intensive care | 102 |
confirmed cases | 101 |
health organization | 100 |
clinical features | 98 |
social distancing | 97 |
tract infections | 97 |
healthcare workers | 95 |
viral rna | 95 |
among patients | 94 |
pregnant women | 93 |
hospital admission | 93 |
tested positive | 92 |
avian influenza | 92 |
viral shedding | 90 |
new york | 90 |
clinical trial | 90 |
disease severity | 88 |
increased risk | 87 |
influenza vaccine | 86 |
infection control | 86 |
care workers | 86 |
index case | 84 |
human metapneumovirus | 84 |
confirmed covid | 84 |
ill patients | 84 |
severe disease | 83 |
ct values | 83 |
viral loads | 83 |
seasonal influenza | 82 |
infectious disease | 81 |
sars coronavirus | 81 |
critically ill | 81 |
coronavirus infection | 79 |
influenza vaccination | 79 |
case patients | 77 |
study period | 76 |
patients infected | 75 |
clinical outcomes | 75 |
diagnostic testing | 74 |
may also | 72 |
antibiotic therapy | 72 |
mycoplasma pneumoniae | 72 |
pandemic influenza | 71 |
respiratory distress | 69 |
influenza pandemic | 69 |
respiratory infections | 69 |
human coronavirus | 68 |
streptococcal pharyngitis | 68 |
immune response | 67 |
underlying medical | 67 |
attack rate | 67 |
viral infection | 67 |
viral infections | 67 |
copies ml | 65 |
test results | 65 |
medical conditions | 64 |
serum samples | 64 |
streptococcus pneumoniae | 64 |
influenza viruses | 63 |
nasopharyngeal swab | 63 |
case series | 63 |
respiratory failure | 63 |
logistic regression | 62 |
performed using | 62 |
antimicrobial therapy | 61 |
care unit | 61 |
older adults | 61 |
tract infection | 61 |
age groups | 61 |
confidence interval | 60 |
clinical course | 59 |
patients hospitalized | 58 |
control measures | 58 |
antibody responses | 58 |
icu admission | 58 |
age group | 57 |
borna disease | 57 |
supplementary table | 57 |
virus infections | 57 |
convalescent plasma | 56 |
control group | 56 |
stem cell | 55 |
rbv rifn | 55 |
asymptomatic individuals | 54 |
infected patients | 54 |
significantly higher | 54 |
adverse events | 54 |
young children | 54 |
otitis media | 53 |
cov infection | 52 |
chest ct | 52 |
controlled trial | 52 |
diagnostic tests | 52 |
higher risk | 52 |
case patient | 51 |
statistically significant | 51 |
general population | 51 |
respiratory disease | 51 |
respiratory specimens | 51 |
staphylococcus aureus | 50 |
antibody response | 49 |
respiratory viral | 49 |
patients receiving | 49 |
pcr test | 48 |
respiratory illness | 48 |
nasopharyngeal swabs | 48 |
within days | 48 |
high risk | 48 |
emergency department | 47 |
sample size | 47 |
risk factor | 47 |
time pcr | 47 |
common cold | 47 |
close contacts | 47 |
viral culture | 47 |
respiratory infection | 46 |
protective equipment | 46 |
current study | 46 |
rsv infection | 46 |
informed consent | 46 |
large number | 45 |
distress syndrome | 45 |
ct value | 45 |
personal protective | 45 |
converting enzyme | 44 |
present study | 44 |
positive results | 44 |
coronavirus pneumonia | 44 |
vaccine effectiveness | 44 |
incubation period | 43 |
time rt | 43 |
observational study | 43 |
control study | 43 |
sore throat | 43 |
odds ratio | 43 |
pcr testing | 43 |
infection prevention | 43 |
median age | 43 |
positive sars | 42 |
gilead sciences | 42 |
pulmonary disease | 42 |
aged years | 42 |
bronchoalveolar lavage | 42 |
specimen collection | 42 |
randomized controlled | 42 |
york city | 42 |
close contact | 42 |
reverse transcription | 41 |
haemophilus influenzae | 41 |
samples obtained | 41 |
within hours | 41 |
respiratory pathogens | 41 |
pcr assay | 41 |
factors associated | 41 |
previous studies | 41 |
south korea | 41 |
cell transplant | 40 |
clinical specimens | 40 |
np swab | 40 |
negative results | 40 |
transmission dynamics | 39 |
diseases society | 39 |
household transmission | 39 |
adult patients | 39 |
mortality rate | 39 |
study population | 39 |
pcr results | 39 |
community transmission | 38 |
hiv infection | 37 |
human immunodeficiency | 37 |
prospective study | 37 |
south africa | 37 |
ebola virus | 37 |
significant difference | 37 |
antiviral therapy | 37 |
predictive value | 37 |
acute rejection | 37 |
institutional review | 36 |
pcr assays | 36 |
asymptomatic cases | 36 |
immunodeficiency virus | 36 |
regression model | 36 |
stool samples | 36 |
treated patients | 36 |
drug administration | 36 |
years old | 36 |
severe cap | 36 |
blood cultures | 36 |
monoclonal antibody | 36 |
infection among | 36 |
mycobacterium tuberculosis | 35 |
asymptomatic patients | 35 |
two groups | 35 |
high viral | 35 |
like illness | 35 |
bal fluid | 35 |
lung injury | 35 |
review board | 35 |
confidence intervals | 35 |
mean age | 34 |
hemolytic streptococci | 34 |
distancing measures | 34 |
less likely | 34 |
symptomatic patients | 34 |
amoy gardens | 34 |
hsct recipients | 34 |
observational studies | 34 |
severe respiratory | 34 |
healthcare settings | 34 |
pneumococcal pneumonia | 34 |
case fatality | 34 |
cell transplantation | 34 |
care facilities | 34 |
cell culture | 34 |
asymptomatic infections | 34 |
bacterial pathogens | 33 |
spike protein | 33 |
bone marrow | 33 |
clinical data | 33 |
associated pneumonia | 33 |
influenza infection | 33 |
reactive protein | 33 |
nasal swabs | 33 |
antiretroviral therapy | 33 |
specific antibodies | 33 |
virus disease | 33 |
diabetes mellitus | 33 |
hubei province | 33 |
neutralizing antibodies | 32 |
chronic obstructive | 32 |
significantly lower | 32 |
immune system | 32 |
patients admitted | 32 |
blood group | 32 |
vaccination program | 32 |
among adults | 32 |
human transmission | 32 |
test result | 32 |
critical care | 32 |
obstructive pulmonary | 32 |
vaccination status | 32 |
viral respiratory | 32 |
coronavirus infections | 32 |
exact test | 32 |
specimens obtained | 32 |
per day | 32 |
cytokine storm | 32 |
icmje form | 32 |
medical records | 31 |
race ethnicity | 31 |
lung disease | 31 |
significant differences | 31 |
rapid antigen | 31 |
immunocompromised patients | 31 |
pneumoniae infection | 31 |
baseline characteristics | 31 |
acute sinusitis | 31 |
antimicrobial stewardship | 31 |
previously reported | 31 |
study design | 31 |
hospital stay | 31 |
igg antibodies | 31 |
antigen tests | 31 |
generation antihistamines | 31 |
findings suggest | 31 |
monoclonal antibodies | 31 |
day mortality | 31 |
hematopoietic stem | 31 |
retrospective cohort | 31 |
parainfluenza virus | 30 |
antibody titers | 30 |
antibiotic treatment | 30 |
significantly associated | 30 |
controlled trials | 30 |
positive patients | 30 |
pleural fluid | 30 |
kidney disease | 30 |
tract disease | 30 |
immune responses | 30 |
first week | 30 |
respiratory samples | 30 |
supplemental oxygen | 30 |
infected pneumonia | 30 |
global health | 30 |
school closures | 29 |
editors consider | 29 |
outcomes among | 29 |
consider relevant | 29 |
new coronavirus | 29 |
mortality among | 29 |
lung transplant | 29 |
positive cases | 29 |
rheumatic fever | 29 |
adults hospitalized | 29 |
sars cov | 29 |
data suggest | 29 |
viral clearance | 29 |
serum therapy | 29 |
heart failure | 29 |
illness onset | 29 |
adverse outcomes | 29 |
antibody therapy | 29 |
culture results | 29 |
clinical manifestations | 29 |
nai treatment | 29 |
chik virus | 28 |
clinical presentation | 28 |
id physicians | 28 |
time reverse | 28 |
severe cases | 28 |
may lead | 28 |
based therapies | 28 |
viral replication | 28 |
infected individuals | 28 |
cell count | 28 |
bcg vaccination | 28 |
transcription polymerase | 28 |
airborne transmission | 28 |
people living | 28 |
patients may | 28 |
emerging infectious | 28 |
attack rates | 28 |
sample collection | 28 |
one study | 27 |
confirmed sars | 27 |
persons aged | 27 |
patient care | 27 |
low viral | 27 |
index patient | 27 |
sinus cavity | 27 |
antibiotic use | 27 |
laboratory workers | 27 |
negative controls | 27 |
human coronaviruses | 27 |
financial support | 27 |
among children | 27 |
study group | 27 |
among hospitalized | 27 |
reverse transcriptase | 27 |
epithelial cells | 27 |
primary outcome | 27 |
fatality rate | 27 |
blood samples | 27 |
standard deviation | 27 |
saliva specimens | 27 |
oxygen saturation | 27 |
vaccine hesitancy | 26 |
serum specimens | 26 |
neutralizing antibody | 26 |
reported cases | 26 |
clinical infectious | 26 |
days prior | 26 |
real time | 26 |
nervous system | 26 |
positive rt | 26 |
throat cultures | 26 |
patients treated | 26 |
cap cases | 26 |
determine whether | 26 |
chronic sinusitis | 26 |
saudi arabia | 26 |
clinical practice | 26 |
nursing home | 26 |
united kingdom | 26 |
hospital mortality | 26 |
independently associated | 26 |
high prevalence | 26 |
disease virus | 26 |
prospective cohort | 26 |
cardiovascular disease | 26 |
continuous variables | 25 |
clinical samples | 25 |
antigen detection | 25 |
human bocavirus | 25 |
bacterial infection | 25 |
patients received | 25 |
urinary antigen | 25 |
future studies | 25 |
severe pneumonia | 25 |
angiotensin ii | 25 |
influenza season | 25 |
severe illness | 25 |
organ failure | 25 |
clinical symptoms | 25 |
term care | 25 |
human milk | 25 |
demographic characteristics | 25 |
chronic kidney | 25 |
available data | 25 |
nasal congestion | 25 |
clinical signs | 25 |
hct recipients | 25 |
serological testing | 25 |
university hospital | 24 |
log copies | 24 |
statistical analysis | 24 |
person transmission | 24 |
retrospective study | 24 |
transport media | 24 |
acute lung | 24 |
recent studies | 24 |
influenza vaccines | 24 |
tested negative | 24 |
maxillary sinus | 24 |
samples collected | 24 |
study participants | 24 |
clinical response | 24 |
recent study | 24 |
ct scan | 24 |
suspected cases | 24 |
serologic testing | 24 |
developing countries | 24 |
healthcare facilities | 24 |
nosocomial transmission | 24 |
family members | 24 |
chest radiograph | 24 |
national health | 24 |
cycle threshold | 24 |
gram stain | 24 |
sciences inc | 24 |
pcr tests | 24 |
combination therapy | 24 |
several limitations | 24 |
bacterial pneumonia | 23 |
patients without | 23 |
sensitivity analyses | 23 |
novel influenza | 23 |
data collection | 23 |
molecular testing | 23 |
blood pressure | 23 |
twice daily | 23 |
hematopoietic cell | 23 |
nested pcr | 23 |
ethics committee | 23 |
control groups | 23 |
multivariate analysis | 23 |
clinical evaluation | 23 |
swab specimens | 23 |
antibiotic resistance | 23 |
septic shock | 23 |
igg antibody | 23 |
randomized clinical | 23 |
acute pharyngitis | 23 |
acute otitis | 23 |
nucleic acids | 23 |
per week | 23 |
pediatric patients | 23 |
mild symptoms | 23 |
adverse effects | 23 |
descriptive study | 23 |
lopinavir ritonavir | 23 |
central nervous | 23 |
based study | 23 |
rheumatoid arthritis | 23 |
clinical improvement | 23 |
receptor blockers | 23 |
million doses | 22 |
cell responses | 22 |
lymphocyte count | 22 |
virus type | 22 |
negative rt | 22 |
significant reduction | 22 |
ct imaging | 22 |
intravenous immunoglobulin | 22 |
clinical severity | 22 |
viral nucleic | 22 |
strong recommendation | 22 |
mildly symptomatic | 22 |
index cases | 22 |
interquartile range | 22 |
congestive heart | 22 |
spreading events | 22 |
angiotensin system | 22 |
health system | 22 |
chronic lung | 22 |
medical condition | 22 |
antiviral activity | 22 |
case reports | 22 |
cov rna | 22 |
healthcare system | 22 |
secondary attack | 22 |
maxillary sinusitis | 22 |
clinical studies | 22 |
medical center | 22 |
clinically relevant | 22 |
serological tests | 22 |
young adults | 22 |
susceptibility testing | 22 |
first positive | 22 |
reported symptoms | 22 |
community outbreak | 22 |
reference method | 22 |
supplementary materials | 21 |
molecular diagnostics | 21 |
among participants | 21 |
performance characteristics | 21 |
marrow transplant | 21 |
ct scans | 21 |
higher viral | 21 |
hiv status | 21 |
included patients | 21 |
cell counts | 21 |
nucleocapsid protein | 21 |
nasopharyngeal aspirate | 21 |
physical examination | 21 |
school closure | 21 |
cytopathic effect | 21 |
acquired infection | 21 |
antiviral treatment | 21 |
year age | 21 |
therapeutic agents | 21 |
may increase | 21 |
test accuracy | 21 |
research grants | 21 |
oral therapy | 21 |
swine workers | 21 |
clinical failure | 21 |
free days | 21 |
treatment effect | 21 |
median duration | 21 |
treatment group | 21 |
wuhan city | 21 |
positive test | 21 |
swab samples | 20 |
clinical laboratory | 20 |
coronary artery | 20 |
rsv viral | 20 |
hmpv infection | 20 |
data analysis | 20 |
household members | 20 |
mg kg | 20 |
surveillance system | 20 |
healthcare systems | 20 |
case report | 20 |
chronic bronchitis | 20 |
multiplex pcr | 20 |
fluid specimens | 20 |
cases per | 20 |
small sample | 20 |
rapid diagnosis | 20 |
asymptomatic case | 20 |
two weeks | 20 |
positive result | 20 |
viral transport | 20 |
sex differences | 20 |
least one | 20 |
requiring hospitalization | 20 |
aerosol transmission | 20 |
blood culture | 20 |
first case | 20 |
respiratory illnesses | 20 |
total number | 20 |
controlled clinical | 20 |
control subjects | 20 |
emergency declarations | 20 |
mainland china | 20 |
infections among | 20 |
human infection | 20 |
medical record | 19 |
viral pathogens | 19 |
north america | 19 |
cov outbreak | 19 |
invasive mechanical | 19 |
empirical therapy | 19 |
sars patients | 19 |
poor outcomes | 19 |
np swabs | 19 |
sars outbreak | 19 |
brain tissue | 19 |
older age | 19 |
pcr positive | 19 |
corresponding author | 19 |
median time | 19 |
healthcare providers | 19 |
will need | 19 |
health departments | 19 |
chinese center | 19 |
nasopharyngeal specimens | 19 |
vertical transmission | 19 |
sectional study | 19 |
another study | 19 |
widely used | 19 |
hospitalization rates | 19 |
described elsewhere | 19 |
children aged | 19 |
suspected covid | 19 |
antimicrobial resistance | 19 |
limited data | 19 |
currently available | 19 |
skilled nursing | 19 |
bacterial infections | 19 |
commercially available | 19 |
acid amplification | 19 |
epidemic curve | 19 |
hospital admissions | 19 |
regression models | 19 |
per patient | 19 |
influenzae type | 19 |
among older | 19 |
icu patients | 19 |
saharan africa | 19 |
early stage | 19 |
herpes simplex | 19 |
oropharyngeal swabs | 19 |
may contribute | 19 |
risk patients | 19 |
causative agent | 19 |
specimen type | 19 |
dear editor | 19 |
supportive care | 19 |
previous study | 19 |
specimen types | 19 |
results suggest | 19 |
family cluster | 19 |
several studies | 18 |
parainfluenza viruses | 18 |
physical distancing | 18 |
information regarding | 18 |
written informed | 18 |
chest radiography | 18 |
immune globulin | 18 |
nitric oxide | 18 |
immunosorbent assay | 18 |
transcriptase polymerase | 18 |
lower mortality | 18 |
microbiology laboratory | 18 |
confirmed case | 18 |
community acquired | 18 |
underlying conditions | 18 |
statistical analyses | 18 |
artery disease | 18 |
nasal mucus | 18 |
additional studies | 18 |
working group | 18 |
tract specimens | 18 |
severe infection | 18 |
hiv viral | 18 |
false negative | 18 |
healthy adults | 18 |
important role | 18 |
diagnostic test | 18 |
epidemiological data | 18 |
clinical diagnosis | 18 |
electronic medical | 18 |
catchment area | 18 |
study drug | 18 |
body mass | 18 |
modelling study | 18 |
case definition | 18 |
study clinical | 18 |
direct contact | 18 |
study showed | 18 |
better understand | 18 |
linked immunosorbent | 18 |
laden aerosols | 18 |
igm antibodies | 18 |
positive predictive | 18 |
imported cases | 18 |
antibody testing | 18 |
selection bias | 18 |
randomized trial | 18 |
dosing regimen | 18 |
molecular diagnostic | 18 |
antimicrobial susceptibility | 18 |
primary patients | 18 |
sas institute | 18 |
regression analysis | 18 |
moderate recommendation | 18 |
categorical variables | 18 |
cafo swine | 18 |
time points | 18 |
national institutes | 18 |
disease outbreak | 18 |
asymptomatic infection | 18 |
mt swabs | 18 |
clinical laboratories | 18 |
previously described | 18 |
resistant staphylococcus | 18 |
interval ci | 18 |
throat swab | 18 |
statistical significance | 17 |
blood cell | 17 |
disease course | 17 |
patients will | 17 |
antigen test | 17 |
mass index | 17 |
epidemiological characteristics | 17 |
severe community | 17 |
reference laboratory | 17 |
important lessons | 17 |
safety profile | 17 |
elderly patients | 17 |
dosing regimens | 17 |
different types | 17 |
level iii | 17 |
even though | 17 |
cohort studies | 17 |
placebo group | 17 |
viral pneumonia | 17 |
surveillance network | 17 |
developed symptoms | 17 |
heart rate | 17 |
western cape | 17 |
global pandemic | 17 |
gold standard | 17 |
testing positive | 17 |
mediated isothermal | 17 |
among individuals | 17 |
rifn therapy | 17 |
antibody positive | 17 |
severe outcomes | 17 |
may reflect | 17 |
observational cohort | 17 |
acute renal | 17 |
potential role | 17 |
throat swabs | 17 |
associated hospitalization | 17 |
stool specimens | 17 |
noninfluenza respiratory | 17 |
children years | 17 |
respiratory diseases | 17 |
clinical care | 17 |
negative test | 17 |
legionella species | 17 |
less common | 17 |
solid organ | 17 |
cells mm | 17 |
may still | 17 |
personal fees | 17 |
symptomatic cases | 17 |
negative predictive | 17 |
animal models | 17 |
small number | 17 |
iii evidence | 17 |
approved cleared | 17 |
cd ra | 16 |
first days | 16 |
contaminated area | 16 |
human challenge | 16 |
organ transplant | 16 |
rapid diagnostic | 16 |
associated infections | 16 |
disease progression | 16 |
fatal cases | 16 |
smallpox vaccination | 16 |
odds ratios | 16 |
amino acid | 16 |
cold symptom | 16 |
nl infection | 16 |
hazard ratio | 16 |
rapid detection | 16 |
room temperature | 16 |
gender differences | 16 |
two patients | 16 |
serial interval | 16 |
study also | 16 |
female patients | 16 |
zhejiang province | 16 |
deep sequencing | 16 |
may occur | 16 |
drug resistance | 16 |
pilot study | 16 |
cd cell | 16 |
prospective studies | 16 |
conjugate vaccine | 16 |
infants born | 16 |
one patient | 16 |
atypical pneumonia | 16 |
bacterial fungal | 16 |
white blood | 16 |
healthcare setting | 16 |
viral genome | 16 |
aspirate specimens | 16 |
among household | 16 |
renal failure | 16 |
interim guidance | 16 |
infectious agents | 16 |
detection rate | 16 |
middle ear | 16 |
older children | 16 |
rhinovirus colds | 16 |
study date | 16 |
computed tomography | 16 |
emergency use | 16 |
pneumonia etiology | 16 |
blood donors | 16 |
remains unclear | 16 |
higher proportion | 16 |
time period | 16 |
acute infection | 16 |
hospitalized adults | 16 |
previous reports | 16 |
patients aged | 16 |
positivity rate | 16 |
compared using | 16 |
mortality due | 16 |
acute wheezing | 16 |
health authorities | 16 |
west africa | 16 |
sputum culture | 16 |
will likely | 16 |
tcid ml | 16 |
tract samples | 16 |
supplementary methods | 16 |
sinus aspirates | 16 |
primary endpoint | 16 |
march th | 16 |
net catchment | 16 |
sars cases | 16 |
receptor binding | 16 |
natural history | 16 |
wbc count | 15 |
clinical impact | 15 |
study found | 15 |
antiviral agents | 15 |
data provided | 15 |
lower among | 15 |
qt prolongation | 15 |
supplemental table | 15 |
microbiologic response | 15 |
study protocol | 15 |
healthy volunteers | 15 |
rate ratios | 15 |
whole blood | 15 |
study treatment | 15 |
nosocomial outbreak | 15 |
antiviral drugs | 15 |
adjusted odds | 15 |
middle meatus | 15 |
national institute | 15 |
inflammatory response | 15 |
empirical antibiotic | 15 |
first two | 15 |
simplex virus | 15 |
hiv testing | 15 |
virus isolation | 15 |
human parechovirus | 15 |
us population | 15 |
systematic reviews | 15 |
will require | 15 |
hiv patients | 15 |
clinical disease | 15 |
passive antibody | 15 |
findings may | 15 |
clean area | 15 |
specimens collected | 15 |
cruise ship | 15 |
coronavirus associated | 15 |
index patients | 15 |
human rhinovirus | 15 |
abo blood | 15 |
health insurance | 15 |
dp swabs | 15 |
renal disease | 15 |
laboratory confirmed | 15 |
significantly reduced | 15 |
corona virus | 15 |
communityacquired pneumonia | 15 |
rsv lrti | 15 |
reported conflicts | 15 |
nsaids users | 15 |
health interventions | 15 |
infected cells | 15 |
primary care | 15 |
cox proportional | 15 |
symptomatic individuals | 15 |
igg avidity | 15 |
level i | 15 |
high mortality | 15 |
plasma samples | 15 |
matched controls | 15 |
cell cultures | 15 |
male sex | 15 |
inclusion criteria | 15 |
relatively low | 15 |
closely related | 15 |
ace expression | 15 |
control strategies | 15 |
level ii | 15 |
infection rates | 15 |
cluster hk | 15 |
symptomatic employees | 15 |
viral detection | 15 |
cryptococcus neoformans | 15 |
retrospective analysis | 15 |
ang ii | 15 |
hospitalization rate | 15 |
secondary infection | 15 |
per year | 15 |
asymptomatic carrier | 15 |
vaccine development | 15 |
pneumococcal polysaccharide | 15 |
asymptomatic sars | 15 |
newly discovered | 15 |
admission decision | 15 |
associated coronavirus | 15 |
study included | 15 |
low prevalence | 15 |
days since | 15 |
acquired infections | 15 |
grants paid | 15 |
negative control | 15 |
assessed using | 15 |
influenza transmission | 15 |
discharged patients | 15 |
well tolerated | 15 |
among persons | 15 |
clinical findings | 15 |
vaccine program | 15 |
healthcare worker | 15 |
hospital discharge | 15 |
serum sample | 15 |
respiratory pcr | 14 |
disease burden | 14 |
proportional hazards | 14 |
host factors | 14 |
acute maxillary | 14 |
cap guidelines | 14 |
health systems | 14 |
million people | 14 |
test performance | 14 |
mortality risk | 14 |
adults aged | 14 |
control practices | 14 |
quantitative pcr | 14 |
mortality rates | 14 |
laboratory testing | 14 |
peripheral blood | 14 |
symptom severity | 14 |
postexposure prophylaxis | 14 |
lactate dehydrogenase | 14 |
hand hygiene | 14 |
human respiratory | 14 |
th epi | 14 |
high level | 14 |
time polymerase | 14 |
recently published | 14 |
conducted using | 14 |
sinus puncture | 14 |
hospitalized children | 14 |
radiological findings | 14 |
cases reported | 14 |
laboratory findings | 14 |
mechanically ventilated | 14 |
pcr positivity | 14 |
clinical stability | 14 |
clinical progression | 14 |
critical illness | 14 |
vitro antiviral | 14 |
oxygen supplementation | 14 |
day course | 14 |
lus score | 14 |
acid extraction | 14 |
medical care | 14 |
studies reported | 14 |
two days | 14 |
antibody levels | 14 |
pneumococcal disease | 14 |
antibody test | 14 |
increased mortality | 14 |
hospitalized covid | 14 |
nab titers | 14 |
i evidence | 14 |
experimental rhinovirus | 14 |
failure requiring | 14 |
ncov infection | 14 |
swine influenza | 14 |
chest pain | 14 |
ii evidence | 14 |
care units | 14 |
cerebrospinal fluid | 14 |
also associated | 14 |
tuberculosis control | 14 |
fungal co | 14 |
hemorrhagic fever | 14 |
among covid | 14 |
among hcws | 14 |
rna detection | 14 |
high rates | 14 |
epidemic curves | 14 |
virus replication | 14 |
severe influenza | 14 |
pseudomonas aeruginosa | 14 |
th week | 14 |
capsular polysaccharide | 14 |
wide range | 14 |
testing capacity | 14 |
severely ill | 14 |
microbial etiology | 14 |
surveillance data | 14 |
neuraminidase inhibitors | 14 |
nonpharmaceutical interventions | 14 |
relatively high | 14 |
aerosolized ribavirin | 14 |
virus load | 14 |
male patients | 14 |
nasopharyngeal samples | 14 |
infection may | 14 |
common respiratory | 14 |
antibody positivity | 14 |
airborne spread | 14 |
respiratory rate | 14 |
may provide | 14 |
also found | 14 |
travel history | 14 |
phase serum | 14 |
data collected | 14 |
readily available | 14 |
symptom screening | 14 |
data available | 14 |
vector control | 14 |
renal transplant | 14 |
clinical research | 14 |
surveillance systems | 14 |
china clinical | 14 |
nasal swab | 14 |
induced sputum | 14 |
acquired respiratory | 14 |
may result | 14 |
influenza rvi | 14 |
time point | 13 |
sample sizes | 13 |
id physician | 13 |
low risk | 13 |
child health | 13 |
internal control | 13 |
considered statistically | 13 |
rates among | 13 |
acid detection | 13 |
newly identified | 13 |
marginal structural | 13 |
prevention strategies | 13 |
thoracic society | 13 |
clinical significance | 13 |
exposed participants | 13 |
hemolytic streptococcal | 13 |
heart disease | 13 |
illness among | 13 |
polysaccharide vaccine | 13 |
adult inpatients | 13 |
analyzed using | 13 |
two cases | 13 |
fisher exact | 13 |
rural areas | 13 |
supplementary appendix | 13 |
contact investigation | 13 |
posted materials | 13 |
pandemic started | 13 |
molecular assays | 13 |
human influenza | 13 |
disease transmission | 13 |
allogeneic hematopoietic | 13 |
secondary cases | 13 |
diagnostic methods | 13 |
semicontaminated area | 13 |
marrow transplantation | 13 |
authors declare | 13 |
received treatment | 13 |
avert hospitalizations | 13 |
receiving presatovir | 13 |
carrier transmission | 13 |
combination treatment | 13 |
vitro diagnostic | 13 |
laboratory diagnosis | 13 |
inflammatory drugs | 13 |
minor criteria | 13 |
higher prevalence | 13 |
per person | 13 |
leukocyte count | 13 |
mitigation strategies | 13 |
microbiologic diagnosis | 13 |
influenza activity | 13 |
transport medium | 13 |
liver disease | 13 |
birth cohort | 13 |
medical history | 13 |
year study | 13 |
benzathine penicillin | 13 |
escherichia coli | 13 |
hispanic black | 13 |
rna clearance | 13 |
conjugate vaccines | 13 |
abu dhabi | 13 |
serum antibody | 13 |
likely due | 13 |
detect sars | 13 |
nasal secretions | 13 |
influenza seasons | 13 |
data capture | 13 |
early transmission | 13 |
clinical microbiology | 13 |
confirmed influenza | 13 |
requiring mechanical | 13 |
available evidence | 13 |
etiologic agent | 13 |
symptoms associated | 13 |
asymptomatic transmission | 13 |
among symptomatic | 13 |
missing data | 13 |
gastrointestinal symptoms | 13 |
early diagnosis | 13 |
sole responsibility | 13 |
health department | 13 |
bacterial load | 13 |
tested using | 13 |
treatment outcomes | 13 |
bacteremic pneumococcal | 13 |
clinical attack | 13 |
health response | 13 |
significant association | 13 |
rvi episodes | 13 |
among healthcare | 13 |
lymphocyte subsets | 13 |
individual patient | 13 |
acute pancreatitis | 13 |
viral agents | 13 |
electronic data | 13 |
clinical criteria | 13 |
results showed | 13 |
days later | 13 |
antibody detection | 13 |
illness severity | 13 |
public sector | 13 |
acute exacerbations | 13 |
cohort entry | 13 |
secondary bacterial | 13 |
healthcare personnel | 13 |
placebo recipients | 13 |
may help | 13 |
multivariable logistic | 13 |
mild covid | 13 |
higher among | 13 |
high levels | 13 |
frequently reported | 13 |
face masks | 13 |
among people | 13 |
pneumonia due | 13 |
cfu ml | 13 |
respiratory pathogen | 13 |
multiplex real | 12 |
new device | 12 |
positive samples | 12 |
scarlet fever | 12 |
suspected sars | 12 |
cd count | 12 |
situation report | 12 |
care worker | 12 |
well documented | 12 |
propensity score | 12 |
cell line | 12 |
smoking status | 12 |
many patients | 12 |
better understanding | 12 |
presatovir treatment | 12 |
patients whose | 12 |
weighted average | 12 |
normal chest | 12 |
zika virus | 12 |
chest radiographs | 12 |
us food | 12 |
neonatal outcomes | 12 |
detection methods | 12 |
pcr kit | 12 |
runny nose | 12 |
highest risk | 12 |
reports grants | 12 |
patient populations | 12 |
based studies | 12 |
considered positive | 12 |
evidence suggests | 12 |
city closure | 12 |
dp swab | 12 |
laboratory values | 12 |
molecular methods | 12 |
treatment failure | 12 |
secondary endpoints | 12 |
coronavirus nl | 12 |
sars epidemic | 12 |
reduced olfaction | 12 |
submitted work | 12 |
comorbid conditions | 12 |
calculated using | 12 |
clinical assessment | 12 |
pleural effusion | 12 |
innate immune | 12 |
presumed asymptomatic | 12 |
age years | 12 |
severe obesity | 12 |
pneumonia outbreak | 12 |
legionnaires disease | 12 |
acute care | 12 |
influenza among | 12 |
barr virus | 12 |
hbov infection | 12 |
greater risk | 12 |
corticosteroid therapy | 12 |
several weeks | 12 |
vaccinated group | 12 |
also reported | 12 |
health conditions | 12 |
age distribution | 12 |
clinical cases | 12 |
cap group | 12 |
multicenter study | 12 |
least days | 12 |
transplant recipient | 12 |
testing strategies | 12 |
diamond princess | 12 |
center experience | 12 |
nursing homes | 12 |
ncov pneumonia | 12 |
virus detected | 12 |
pneumoniae infections | 12 |
antimicrobial agents | 12 |
following criteria | 12 |
younger adults | 12 |
control drug | 12 |
study reported | 12 |
asymptomatic persons | 12 |
severe coronavirus | 12 |
guideline panel | 12 |
multiplex rt | 12 |
pleconaril recipients | 12 |
ct findings | 12 |
coronavirus oc | 12 |
nursing facility | 12 |
april th | 12 |
rna virus | 12 |
high proportion | 12 |
authors report | 12 |
commonly reported | 12 |
average change | 12 |
clinical benefit | 12 |
unexposed participants | 12 |
pneumococcal bacteremia | 12 |
diagnostic device | 12 |
asymptomatic covid | 12 |
vaccination coverage | 12 |
rna viruses | 12 |
potential confounding | 12 |
doses per | 12 |
myocardial infarction | 12 |
respiratory protection | 12 |
patients requiring | 12 |
acute bacterial | 12 |
ventilated patients | 12 |
clinical management | 12 |
disease caused | 12 |
results may | 12 |
rhinovirus infection | 12 |
presumed microbiologic | 12 |
cumulative incidence | 12 |
reduced mortality | 12 |
metapneumovirus infection | 12 |
angiotensin converting | 12 |
care hospital | 12 |
health officials | 12 |
reported confirmed | 12 |
type i | 12 |
prevalence among | 12 |
angiotensin receptor | 12 |
pathological changes | 12 |
cases occurred | 12 |
disease among | 12 |
phylogenetic analysis | 12 |
rsv cohort | 12 |
adjacent bay | 12 |
chikungunya virus | 12 |
outpatient visits | 12 |
specific antibody | 12 |
influenza testing | 12 |
practice guidelines | 12 |
vast majority | 12 |
million cases | 11 |
challenge study | 11 |
normal range | 11 |
older patients | 11 |
secondary infections | 11 |
infections may | 11 |
spatial distribution | 11 |
direct evidence | 11 |
sputum specimens | 11 |
nasopharyngeal aspirates | 11 |
viral etiology | 11 |
much lower | 11 |
clinical performance | 11 |
worse outcomes | 11 |
patients presenting | 11 |
also observed | 11 |
hospital infection | 11 |
clinical reference | 11 |
protease inhibitor | 11 |
series analysis | 11 |
selected patients | 11 |
single center | 11 |
new cases | 11 |
vs days | 11 |
throat culture | 11 |
transplant patients | 11 |
cesarean section | 11 |
higher rate | 11 |
commonly used | 11 |
nosocomial infection | 11 |
recent report | 11 |
rate among | 11 |
pneumococcal conjugate | 11 |
grade ii | 11 |
local health | 11 |
fatality rates | 11 |
sputum samples | 11 |
humoral response | 11 |
identify patients | 11 |
transmission pairs | 11 |
invasive pneumococcal | 11 |
infection within | 11 |
rsv infections | 11 |
first cases | 11 |
healthy individuals | 11 |
clinical case | 11 |
tertiary care | 11 |
new jersey | 11 |
positive viral | 11 |
recently reported | 11 |
virus detection | 11 |
received research | 11 |
medical students | 11 |
exclusion criteria | 11 |
mexico city | 11 |
xtag rvp | 11 |
lrtd progression | 11 |
pharmaceutical interventions | 11 |
based cohort | 11 |
latent tuberculosis | 11 |
cell entry | 11 |
autopsy laboratory | 11 |
op swab | 11 |
lung ultrasound | 11 |
diagnostic assays | 11 |
fatigue syndrome | 11 |
symptom profiles | 11 |
decision making | 11 |
first covid | 11 |
diagnostic devices | 11 |
five days | 11 |
blood levels | 11 |
estimated using | 11 |
orf ab | 11 |
higher rates | 11 |
center study | 11 |
virus origins | 11 |
tumor necrosis | 11 |
see supplementary | 11 |
received rbv | 11 |
lac dph | 11 |
laboratory tests | 11 |
second week | 11 |
using sas | 11 |
three patients | 11 |
ct score | 11 |
drotrecogin alfa | 11 |
vital signs | 11 |
swine farms | 11 |
authors thank | 11 |
hospitalized cases | 11 |
nab levels | 11 |
also included | 11 |
molecular detection | 11 |
special issue | 11 |
nosocomial pneumonia | 11 |
second index | 11 |
streptococcal infections | 11 |
sot recipients | 11 |
hematologic malignancies | 11 |
infections caused | 11 |
infectious virus | 11 |
serious adverse | 11 |
efficacy population | 11 |
chronic fatigue | 11 |
cov transmission | 11 |
prior studies | 11 |
long term | 11 |
clinical cure | 11 |
saliva samples | 11 |
resistant tuberculosis | 11 |
necrosis factor | 11 |
tuberculosis notifications | 11 |
pev infections | 11 |
prospective observational | 11 |
isothermal amplification | 11 |
urinary tract | 11 |
viral cultures | 11 |
pediatric emergency | 11 |
infected animals | 11 |
huh cells | 11 |
underlying disease | 11 |
noninvasive ventilation | 11 |
smallpox virus | 11 |
paranasal sinuses | 11 |
four patients | 11 |
mean time | 11 |
mg twice | 11 |
molecular tests | 11 |
common symptoms | 11 |
fluid dynamics | 11 |
patients recovered | 11 |
among health | 11 |
versus non | 11 |
abdominal pain | 11 |
different respiratory | 11 |
side effects | 11 |
care settings | 11 |
publicly reported | 11 |
associated hospitalizations | 11 |
viral illness | 11 |
much higher | 11 |
clinical relevance | 11 |
supplementary material | 11 |
acute phase | 11 |
chik fever | 11 |
may reduce | 11 |
two consecutive | 11 |
challenge trials | 11 |
severe outcome | 11 |
electronic health | 11 |
common among | 11 |
chronic hepatitis | 11 |
positive individuals | 11 |
total nucleic | 11 |
severe symptoms | 11 |
viral dynamics | 11 |
flu seasons | 11 |
diseases online | 11 |
retrospective studies | 11 |
protective effect | 11 |
coronavirus outbreak | 11 |
mg dl | 11 |
potential therapeutic | 11 |
patients included | 11 |
sinus aspirate | 11 |
laboratory test | 11 |
infections due | 11 |
detectable antibodies | 10 |
vero cells | 10 |
negative patients | 10 |
clinical evidence | 10 |
cd cells | 10 |
tropical diseases | 10 |
asymptomatic carriers | 10 |
also collected | 10 |
droplet precautions | 10 |
pcr diagnostic | 10 |
specific primers | 10 |
particularly important | 10 |
capture elisa | 10 |
inflammatory markers | 10 |
sneeze reflex | 10 |
significantly increased | 10 |
aspirate cultures | 10 |
advisory committee | 10 |
influenza epidemics | 10 |
literature review | 10 |
related outcomes | 10 |
detectable viral | 10 |
pacific region | 10 |
oxford immunotec | 10 |
kidney injury | 10 |
gustatory dysfunction | 10 |
distant bays | 10 |
using data | 10 |
time series | 10 |
doctor shopping | 10 |
developed severe | 10 |
practice guideline | 10 |
measles virus | 10 |
population outflow | 10 |
pbpk models | 10 |
diagnostic panel | 10 |
brain barrier | 10 |
clinical study | 10 |
positive controls | 10 |
etiologic agents | 10 |
virological assessment | 10 |
valentine leukocidin | 10 |
pcr method | 10 |
specific igm | 10 |
flu season | 10 |
turnaround time | 10 |
month period | 10 |
serological assays | 10 |
ribavirin use | 10 |
plasma therapy | 10 |
laboratory methods | 10 |
time nested | 10 |
secondary outcomes | 10 |
survivor group | 10 |
therapeutic trials | 10 |
genetic diversity | 10 |
influenza outbreak | 10 |
epidemiological studies | 10 |
may play | 10 |
pneumonia among | 10 |
population density | 10 |
less severe | 10 |
causative pathogen | 10 |
term outcomes | 10 |
respiratory secretions | 10 |
data regarding | 10 |
limited settings | 10 |
tests may | 10 |
first dose | 10 |
different time | 10 |
loading dose | 10 |
studies showed | 10 |
specimens tested | 10 |
expectorated sputum | 10 |
took place | 10 |
sensitivity analysis | 10 |
mers patients | 10 |
mini kit | 10 |
clinical decision | 10 |
op swabs | 10 |
chlamydia trachomatis | 10 |
factors may | 10 |
antibody titer | 10 |
elderly people | 10 |
igg levels | 10 |
randomly selected | 10 |
virus culture | 10 |
lupus erythematosus | 10 |
health commission | 10 |
studies using | 10 |
th day | 10 |
patients reported | 10 |
healthy children | 10 |
care personnel | 10 |
neglected tropical | 10 |
clinical parameters | 10 |
rhinovirus infections | 10 |
etiologic diagnosis | 10 |
health emergency | 10 |
clinical specimen | 10 |
stool specimen | 10 |
included studies | 10 |
specific treatment | 10 |
studies reporting | 10 |
pneumonia requiring | 10 |
meningococcal disease | 10 |
described previously | 10 |
temporal dynamics | 10 |
higher mortality | 10 |
early detection | 10 |
homeless shelters | 10 |
tuberculosis patients | 10 |
first time | 10 |
associated sars | 10 |
blood agar | 10 |
use authorization | 10 |
significantly different | 10 |
hospitalization surveillance | 10 |
among asymptomatic | 10 |
without hiv | 10 |
laboratory data | 10 |
year period | 10 |
older individuals | 10 |
detection rates | 10 |
previously healthy | 10 |
population movement | 10 |
ace receptor | 10 |
glass opacities | 10 |
cases among | 10 |
also assessed | 10 |
first months | 10 |
tracing efforts | 10 |
health services | 10 |
cystic fibrosis | 10 |
chronic diseases | 10 |
viral transmission | 10 |
presymptomatic transmission | 10 |
risk populations | 10 |
probe prodesse | 10 |
current evidence | 10 |
influenza pandemics | 10 |
disposable gown | 10 |
disease may | 10 |
atypical pathogens | 10 |
within households | 10 |
randomised controlled | 10 |
immune function | 10 |
general medical | 10 |
ec values | 10 |
inactivated influenza | 10 |
hiv aids | 10 |
different dosing | 10 |
vaccination programs | 10 |
closing schools | 10 |
multivariate analyses | 10 |
health research | 10 |
immune sera | 10 |
observational data | 10 |
aldosterone system | 10 |
study shows | 10 |
ebola outbreak | 10 |
vaginal delivery | 10 |
positive blood | 10 |
patient population | 10 |
severe sepsis | 10 |
mortality associated | 10 |
negative bacilli | 10 |
th percentile | 10 |
early treatment | 10 |
differential diagnosis | 10 |
blood sample | 10 |
testing resources | 10 |
pneumonia associated | 10 |
care facility | 10 |
symptomatic covid | 10 |
infection risk | 10 |
section ct | 10 |
protease inhibitors | 10 |
complete resolution | 10 |
infected children | 10 |
positive np | 10 |
electron microscopy | 10 |
protective immunity | 10 |
bacterial pathogen | 10 |
outpatient treatment | 10 |
renal function | 10 |
mild disease | 10 |
general hospital | 10 |
common causes | 10 |
wide variety | 10 |
controlled studies | 10 |
critical cases | 10 |
emergency departments | 10 |
false positive | 9 |
specific antiviral | 9 |
palm civets | 9 |
systemic lupus | 9 |
alfa activated | 9 |
san francisco | 9 |
less sensitive | 9 |
provide evidence | 9 |
immortal time | 9 |
igm elisa | 9 |
living unsheltered | 9 |
severe clinical | 9 |
chik infection | 9 |
case finding | 9 |
steroidal anti | 9 |
preterm delivery | 9 |
infectious agent | 9 |
nearly half | 9 |
ras inhibitors | 9 |
vitro activity | 9 |
forward transmission | 9 |
host cells | 9 |
study may | 9 |
studies suggest | 9 |
diagnostic procedures | 9 |
antiviral effect | 9 |
pool size | 9 |
drug interactions | 9 |
relatively small | 9 |
required hospitalization | 9 |
west nile | 9 |
pev detection | 9 |
large proportion | 9 |
computational fluid | 9 |
occupational risk | 9 |
false positives | 9 |
three groups | 9 |
acid testing | 9 |
medical staff | 9 |
antibiotic prescribing | 9 |
single dose | 9 |
become available | 9 |
medical college | 9 |
lung aspiration | 9 |
since onset | 9 |
transmission potential | 9 |
diagnosis interval | 9 |
transmission heterogeneity | 9 |
may need | 9 |
febrile infants | 9 |
one day | 9 |
applied biosystems | 9 |
clinical information | 9 |
biopsy specimens | 9 |
antiviral drug | 9 |
two case | 9 |
nasal passages | 9 |
clostridium difficile | 9 |
patients might | 9 |
high titers | 9 |
hypothetical virus | 9 |
transmission within | 9 |
retrospective case | 9 |
possible cause | 9 |
sars pneumonia | 9 |
antibody tests | 9 |
outbreak associated | 9 |
tuberculosis treatment | 9 |
acute kidney | 9 |
infection due | 9 |
times daily | 9 |
may require | 9 |
aerosol generation | 9 |
higher number | 9 |
otherwise healthy | 9 |
severity scenario | 9 |
acute rheumatic | 9 |
plus bal | 9 |
biosafety level | 9 |
safety monitoring | 9 |
lavage fluid | 9 |
received grants | 9 |
pulmonary infiltrates | 9 |
current recommendations | 9 |
diagnostic accuracy | 9 |
classical ras | 9 |
laboratory director | 9 |
mild respiratory | 9 |
frontline hcws | 9 |
episodes per | 9 |
clinical use | 9 |
pcr using | 9 |
affected countries | 9 |
positive specimens | 9 |
rapid tests | 9 |
isolation precautions | 9 |
rhesus macaques | 9 |
pulmonary edema | 9 |
first day | 9 |
bronchiolitis obliterans | 9 |
administrative data | 9 |
replacement therapy | 9 |
protective clothing | 9 |
cell lines | 9 |
consultant fees | 9 |
studies will | 9 |
tract complications | 9 |
probable sars | 9 |
tests will | 9 |
repeat testing | 9 |
oral transmission | 9 |
intervention arm | 9 |
participants reported | 9 |
effect size | 9 |
lung involvement | 9 |
blood glucose | 9 |
using different | 9 |
important cause | 9 |
vitro susceptibility | 9 |
congregate settings | 9 |
specimen obtained | 9 |
laboratory confirmation | 9 |
influenza cohort | 9 |
among women | 9 |
lung tissue | 9 |
symptom diaries | 9 |
research ethics | 9 |
patient characteristics | 9 |
washington state | 9 |
pev infection | 9 |
lung pathology | 9 |
cov case | 9 |
require hospitalization | 9 |
respiratory droplets | 9 |
pneumonia cases | 9 |
convenience sample | 9 |
clinical outcome | 9 |
research electronic | 9 |
corticosteroid treatment | 9 |
tissue culture | 9 |
surveillance testing | 9 |
bacterial loads | 9 |
mixed infections | 9 |
immune complex | 9 |
novel human | 9 |
active control | 9 |
oseltamivir treatment | 9 |
including sars | 9 |
dry cough | 9 |
igm antibody | 9 |
virus carriers | 9 |
test negative | 9 |
committee members | 9 |
throat wash | 9 |
tb patients | 9 |
genomic characterisation | 9 |
school staff | 9 |
risk groups | 9 |
fob plus | 9 |
high sensitivity | 9 |
healthcare professionals | 9 |
cns manifestations | 9 |
disease prevention | 9 |
higher bmi | 9 |
consulting fees | 9 |
patient outcomes | 9 |
two studies | 9 |
buffer zone | 9 |
communicable diseases | 9 |
study using | 9 |
organ transplantation | 9 |
onset date | 9 |
luminex xtag | 9 |
coronavirus indicating | 9 |
risk areas | 9 |
first report | 9 |
higher levels | 9 |
validation cohort | 9 |
inverse probability | 9 |
abnormal chest | 9 |
acid tests | 9 |
reference standard | 9 |
widespread testing | 9 |
case detection | 9 |
negative pressure | 9 |
international spread | 9 |
hospital day | 9 |
may include | 9 |
community respiratory | 9 |
analytical sensitivity | 9 |
newly recognized | 9 |
nd week | 9 |
wenzhou anti | 9 |
familial cluster | 9 |
per million | 9 |
fecal samples | 9 |
pathogen detection | 9 |
influenza rvis | 9 |
cape province | 9 |
epidemiological features | 9 |
early march | 9 |
coronavirus hku | 9 |
blood gas | 9 |
published studies | 9 |
quantitative detection | 9 |
immunomodulatory effects | 9 |
diarrheal stool | 9 |
productive cough | 9 |
panel agreed | 9 |
vaccination rate | 9 |
liver transplant | 9 |
neuraminidase inhibitor | 9 |
potential risk | 9 |
neisseria gonorrhoeae | 9 |
adverse reactions | 9 |
new human | 9 |
bpa group | 9 |
flnp swabs | 9 |
cause mortality | 9 |
complete case | 9 |
enzyme inhibitors | 9 |
serial intervals | 9 |
income countries | 9 |
visceral leishmaniasis | 9 |
optical density | 9 |
immunocompromised hosts | 9 |
nosocomial infections | 9 |
system inhibitors | 9 |
bacterial co | 9 |
dose glucocorticoids | 9 |
remains unknown | 9 |
lymph nodes | 9 |
arterial blood | 9 |
analysis showed | 9 |
bacterial etiology | 9 |
low cd | 9 |
detectable sars | 9 |
supplementary information | 8 |
therapeutic option | 8 |
potential confounders | 8 |
persistent infection | 8 |
higher mean | 8 |
general guidelines | 8 |
study sites | 8 |
hydroxychloroquine sulfate | 8 |
chart review | 8 |
preliminary report | 8 |
ciz sha | 8 |
becton dickinson | 8 |
cell activation | 8 |
three times | 8 |
inconclusive results | 8 |
blood transfusion | 8 |
significant decrease | 8 |
surgical masks | 8 |
therapeutic agent | 8 |
symptoms reported | 8 |
evidence supporting | 8 |
aspartate aminotransferase | 8 |
fusion inhibitor | 8 |
sample obtained | 8 |
decisions regarding | 8 |
human services | 8 |
patients also | 8 |
round pcr | 8 |
health surveillance | 8 |
psi score | 8 |
limited number | 8 |
post hoc | 8 |
individuals may | 8 |
nsaids use | 8 |
first reported | 8 |
viral genomes | 8 |
lymphatic filariasis | 8 |
left lower | 8 |
cold symptoms | 8 |
multivariate logistic | 8 |
antimicrobial agent | 8 |
first identified | 8 |
viral diseases | 8 |
neisseria meningitidis | 8 |
muscarinic receptors | 8 |
pediatric cap | 8 |
may limit | 8 |
microbiological diagnosis | 8 |
first tested | 8 |
studies found | 8 |
etiology research | 8 |
virus types | 8 |
pdm vaccine | 8 |
urine samples | 8 |
influenza infections | 8 |
healthcare provider | 8 |
local public | 8 |
immunization practices | 8 |
directed therapy | 8 |
sars virus | 8 |
sample pooling | 8 |
different clinical | 8 |
school community | 8 |
using standard | 8 |
respiratory tracts | 8 |
age months | 8 |
attributable risk | 8 |
recent years | 8 |
refractory covid | 8 |
among influenza | 8 |
group included | 8 |
respiratory specimen | 8 |
may st | 8 |
reference laboratories | 8 |
chlamydial infection | 8 |
short period | 8 |
spread rapidly | 8 |
core airports | 8 |
microbiological methods | 8 |
oropharyngeal saliva | 8 |
infection occurred | 8 |
may affect | 8 |
confirmed mers | 8 |
clinically significant | 8 |
collection methods | 8 |
class ii | 8 |
susceptibility patterns | 8 |
regression discontinuity | 8 |
np op | 8 |
first weeks | 8 |
data show | 8 |
variola virus | 8 |
entire population | 8 |
may represent | 8 |
previously published | 8 |
cleared naats | 8 |
hajj pilgrims | 8 |
positive rate | 8 |
body fluids | 8 |
index day | 8 |
acquired sinusitis | 8 |
upper airway | 8 |
cid ciz | 8 |
rna load | 8 |
potential impact | 8 |
nasopharyngeal secretions | 8 |
virus transmission | 8 |
end point | 8 |
viruses among | 8 |
mortality data | 8 |
influenza may | 8 |
routine clinical | 8 |
sinus disease | 8 |
outside wuhan | 8 |
stewardship programs | 8 |
zoster virus | 8 |
gene targets | 8 |
health responses | 8 |
risk among | 8 |
per capita | 8 |
treatment regimen | 8 |
required mechanical | 8 |
one case | 8 |
index test | 8 |
yielded positive | 8 |
reduced sense | 8 |
different countries | 8 |
many countries | 8 |
confounding factors | 8 |
sars survivors | 8 |
clinically proven | 8 |
two cohorts | 8 |
dendritic cells | 8 |
quality control | 8 |
rd week | 8 |
comorbidity index | 8 |
will provide | 8 |
prognostic factors | 8 |
among different | 8 |
unpublished data | 8 |
may benefit | 8 |
develop symptoms | 8 |
treatment effects | 8 |
live virus | 8 |
blood groups | 8 |
serious infections | 8 |
copies per | 8 |
new technology | 8 |
concerns regarding | 8 |
complete blood | 8 |
fda clearance | 8 |
needle aspiration | 8 |
peh living | 8 |
increased incidence | 8 |
internal medicine | 8 |
findings provide | 8 |
participants reporting | 8 |
interactive web | 8 |
may impact | 8 |
positive cultures | 8 |
gargle lavage | 8 |
phase trial | 8 |
cell leukemia | 8 |
pcr negative | 8 |
outpatient setting | 8 |
acute lower | 8 |
multiplex assay | 8 |
sputum production | 8 |
april st | 8 |
potential pathogens | 8 |
possible role | 8 |
preventive measures | 8 |
also important | 8 |
antiviral effects | 8 |
childhood pneumonia | 8 |
new zealand | 8 |
important outcomes | 8 |
medical ward | 8 |
acquired cases | 8 |
bacterial culture | 8 |
amplicor mycobacterium | 8 |
first wave | 8 |
laboratory results | 8 |
syndrome among | 8 |
influenza antiviral | 8 |
vaccine candidates | 8 |
human health | 8 |
hospital outbreak | 8 |
developing severe | 8 |
time since | 8 |
affected province | 8 |
school closings | 8 |
gene sequencing | 8 |
mononuclear cells | 8 |
cause severe | 8 |
linear regression | 8 |
months old | 8 |
panel considered | 8 |
ivd device | 8 |
certainty evidence | 8 |
live attenuated | 8 |
leading cause | 8 |
ii receptor | 8 |
approximately one | 8 |
influenza cases | 8 |
western blot | 8 |
quantitative polymerase | 8 |
data interpretation | 8 |
universal bcg | 8 |
children human | 8 |
origin influenza | 8 |
health measures | 8 |
pandemic caused | 8 |
virus shedding | 8 |
community spread | 8 |
case definitions | 8 |
environmental contamination | 8 |
fees honoraria | 8 |
endotracheal intubation | 8 |
patients died | 8 |
generation cases | 8 |
sars among | 8 |
nosocomial influenza | 8 |
seroprevalence surveys | 8 |
resistant organisms | 8 |
vaccination may | 8 |
publication bias | 8 |
transmission risk | 8 |
high specificity | 8 |
host infectivity | 8 |
herd immunity | 8 |
bat origin | 8 |
population level | 8 |
ambulatory patients | 8 |
therapy may | 8 |
disease associated | 8 |
serious illness | 8 |
potential benefits | 8 |
positive control | 8 |
lung aspirate | 8 |
multiple organ | 8 |
mm hg | 8 |
individual variation | 8 |
convalescent blood | 8 |
disease prevalence | 8 |
mild illness | 8 |
prevent nosocomial | 8 |
household contact | 8 |
trial design | 8 |
natural colds | 8 |
tuberculosis infection | 8 |
ng ml | 8 |
propensity scores | 8 |
clinical spectrum | 8 |
china epidemiological | 8 |
comparative study | 8 |
direct test | 8 |
chronic conditions | 8 |
patients diagnosed | 8 |
colds due | 8 |
children hospitalized | 8 |
quality assurance | 8 |
indicating person | 8 |
may cause | 8 |
lymphocytic choriomeningitis | 8 |
tract illness | 8 |
supply chain | 8 |
charlson comorbidity | 8 |
home orders | 8 |
cancer patients | 8 |
testing strategy | 8 |
future clinical | 8 |
high clinical | 8 |
demographic data | 8 |
new respiratory | 8 |
staff members | 8 |
agents acting | 8 |
observation period | 8 |
asymptomatic children | 8 |
microbiologic eradication | 8 |
severe infections | 8 |
hospitalized adult | 8 |
evaluated using | 8 |
multivariable analysis | 8 |
australian children | 8 |
poisson regression | 8 |
reducing transmission | 8 |
genome sequencing | 8 |
may vary | 8 |
unique opportunity | 8 |
probable bat | 8 |
presymptomatic sars | 8 |
primary case | 8 |
using spss | 8 |
highly effective | 8 |
outpatient settings | 8 |
guideline development | 8 |
princess cruise | 8 |
thank dr | 8 |
alanine aminotransferase | 8 |
disease clinical | 8 |
infant outcomes | 8 |
higher frequency | 8 |
direct contacts | 8 |
well known | 8 |
preventable diseases | 8 |
prior antibiotic | 8 |
important implications | 8 |
daily symptom | 8 |
aspirate culture | 8 |
posterior oropharyngeal | 8 |
lancet infectious | 8 |
partial pressure | 8 |
day care | 8 |
confirmatory testing | 8 |
differ significantly | 8 |
perch study | 8 |
liver function | 8 |
national surveillance | 8 |
six days | 8 |
health facilities | 8 |
data may | 8 |
days following | 8 |
emerging infections | 8 |
antibiotic dose | 8 |
overall prevalence | 8 |
common pathogens | 8 |
collected saliva | 8 |
specific symptoms | 8 |
risk stratification | 8 |
hcq blood | 8 |
health record | 8 |
inflammatory cytokines | 8 |
temporal profiles | 8 |
control efforts | 7 |
human population | 7 |
viral hemorrhagic | 7 |
cytokine release | 7 |
age cohorts | 7 |
los angeles | 7 |
type diabetes | 7 |
chronic respiratory | 7 |
blood products | 7 |
nationwide analysis | 7 |
rank test | 7 |
fit testing | 7 |
pulse oximetry | 7 |
pcr amplification | 7 |
rna mini | 7 |
population included | 7 |
slightly lower | 7 |
north carolina | 7 |
institute inc | 7 |
less effective | 7 |
women admitted | 7 |
mediated immunity | 7 |
causal relationship | 7 |
renal insufficiency | 7 |
viral pathogen | 7 |
young infants | 7 |
contact matrix | 7 |
secondary transmission | 7 |
patients showed | 7 |
human cells | 7 |
socioeconomic status | 7 |
among pwh | 7 |
may explain | 7 |
many parts | 7 |
mental health | 7 |
taken together | 7 |
hyperimmune globulins | 7 |
employee testing | 7 |
composite endpoint | 7 |
may indicate | 7 |
negative cases | 7 |
label non | 7 |
frontline healthcare | 7 |
based antibiotic | 7 |
eligibility criteria | 7 |
randomized trials | 7 |
unit admission | 7 |
standard flnp | 7 |
current clinical | 7 |
entry depends | 7 |
hiv epidemic | 7 |
stool sample | 7 |
bacterial species | 7 |
sample well | 7 |
rapid influenza | 7 |
samples tested | 7 |
clinical efficacy | 7 |
chronic disease | 7 |
molecular epidemiology | 7 |
social media | 7 |
infection human | 7 |
controlled study | 7 |
care services | 7 |
pneumococcal vaccine | 7 |
ground glass | 7 |
fda guidance | 7 |
doses administered | 7 |
among plwh | 7 |
emergency response | 7 |
term follow | 7 |
hospitalization due | 7 |
lung cancer | 7 |
nlus score | 7 |
first step | 7 |
mathematical modeling | 7 |
disease onset | 7 |
household transmissions | 7 |
serological investigation | 7 |
kidney transplant | 7 |
patient management | 7 |
hand washing | 7 |
nebulized ifn | 7 |
emergency medical | 7 |
preliminary results | 7 |
recently emerged | 7 |
syndrome virus | 7 |
ventilation system | 7 |
nasal samples | 7 |
secondary analysis | 7 |
invasive bacterial | 7 |
winter months | 7 |
study provides | 7 |
lower limit | 7 |
short course | 7 |
study demonstrates | 7 |
nasal rsv | 7 |
general practitioners | 7 |
syndromic surveillance | 7 |
precautionary practices | 7 |
load dynamics | 7 |
acute expiratory | 7 |
nile virus | 7 |
seafood market | 7 |
especially among | 7 |
inflammatory syndrome | 7 |
st century | 7 |
antibiotic stewardship | 7 |
therapeutic intervention | 7 |
viral inoculum | 7 |
clinical presentations | 7 |
pulmonary infection | 7 |
existing evidence | 7 |
infection clinical | 7 |
resistant strains | 7 |
pulmonary function | 7 |
health disparities | 7 |
among female | 7 |
leukemia virus | 7 |
urgently needed | 7 |
control studies | 7 |
infection date | 7 |
treatment groups | 7 |
pcr cycle | 7 |
quantitative rt | 7 |
screening program | 7 |
prolonged viral | 7 |
find evidence | 7 |
platelet count | 7 |
risks associated | 7 |
elevated ldh | 7 |
residential buildings | 7 |
consecutive patients | 7 |
amplification tests | 7 |
low ct | 7 |
known viruses | 7 |
pcr confirmed | 7 |
ongoing covid | 7 |
reduce transmission | 7 |
confirmed coronavirus | 7 |
blood specimens | 7 |
tract viral | 7 |
adaptive immune | 7 |
graft rejection | 7 |
intended use | 7 |
lamp assay | 7 |
routine diagnostic | 7 |
virus challenge | 7 |
risk class | 7 |
low due | 7 |
reported loss | 7 |
without influenza | 7 |
current outbreak | 7 |
universal transport | 7 |
amplified mycobacterium | 7 |
clinical entity | 7 |
clinical settings | 7 |
based case | 7 |
two months | 7 |
human antibody | 7 |
prospectively collected | 7 |
enzyme immunoassay | 7 |
effector memory | 7 |
travel restrictions | 7 |
detectable rna | 7 |
highly contagious | 7 |
time bias | 7 |
mers coronavirus | 7 |
third wave | 7 |
risk adults | 7 |
outbreak investigation | 7 |
health problem | 7 |
overall certainty | 7 |
toxic shock | 7 |
virus panel | 7 |
body weight | 7 |
vaccination policy | 7 |
breaths min | 7 |
expiratory wheezing | 7 |
allogeneic hsct | 7 |
affected patients | 7 |
bcg vaccine | 7 |
nonsteroidal anti | 7 |
supplement sponsorship | 7 |
million persons | 7 |
tertiary hospital | 7 |
secondary case | 7 |
recall bias | 7 |
positivity rates | 7 |
nucleotide sequences | 7 |
deaths per | 7 |
pandemic potential | 7 |
significant impact | 7 |
identify risk | 7 |
viral illnesses | 7 |
chronic pulmonary | 7 |
transbronchial biopsies | 7 |
pwh hospitalized | 7 |
respiratory fluoroquinolone | 7 |
acute exacerbation | 7 |
patients using | 7 |
specific pathogens | 7 |
ongoing clinical | 7 |
last years | 7 |
nursing facilities | 7 |
remain infectious | 7 |
based surveillance | 7 |
immunocompromised host | 7 |
peak viral | 7 |
early spring | 7 |
current pandemic | 7 |
manifestations associated | 7 |
clinical virology | 7 |
clients living | 7 |
treatment protocol | 7 |
diagnostic value | 7 |
acute lrtis | 7 |
plasma concentrations | 7 |
acute community | 7 |
frequently observed | 7 |
several factors | 7 |
versus placebo | 7 |
national lockdown | 7 |
bacterial sinusitis | 7 |
mean ct | 7 |
specific igg | 7 |
droplet spread | 7 |
accuracy studies | 7 |
urine specimens | 7 |
pneumonia may | 7 |
week period | 7 |
control covid | 7 |
persistently infected | 7 |
becomes available | 7 |
transmission events | 7 |
chloroquine phosphate | 7 |
clinical deterioration | 7 |
immune cells | 7 |
analysis revealed | 7 |
mouse hepatitis | 7 |
testing centers | 7 |
especially important | 7 |
health crisis | 7 |
african americans | 7 |
king county | 7 |
antibacterial agents | 7 |